spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  hydroxyurea 

 HSMN NewsFeed - 3 Nov 2020
FDA Approves Updated Label for Endari(R)
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Sep 2019
Emmaus Life Sciences Reinforces Positive Outcomes of Endari(R) Clinical Trials, Including Efficacy Findings That Led to FDA Approval
Biopharmaceuticals
 HSMN NewsFeed - 21 Aug 2018
Siklos(R), the first and only hydroxyurea-based treatment for pediatric patients with sickle cell anemia, now available in retail pharmacies
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 20 Jul 2018
FDA Grants Approval of TIBSOVO(R), the First Oral, Targeted Therapy for Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia and an IDH1 Mutation
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Feb 2016
Incyte Announces Decision to Discontinue JANUS Studies of Ruxolitinib plus Capecitabine in Patients with Advanced or Metastatic Pancreatic Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 17 Mar 2015
Jakavi(R) (ruxolitinib) Receives European Commission Approval as First Targeted Therapy for Patients with Polycythemia Vera
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Mar 2014
Incyte Announces Positive Top-Line Results from Phase III Study of Ruxolitinib in Patients with Polycythemia Vera
Biopharmaceuticals
 HSMN NewsFeed - 9 Jan 2014
Biogen Idec and Sangamo BioSciences Announce Global Collaboration to Develop Treatments for Hemoglobinopathies
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2012
Teva Receives Approval For SYNRIBO(TM) (Omacetaxine Mepesuccinate) for Injection
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 12 Mar 2012
HemaQuest Pharmaceuticals Raises $13 Million in Series B Extension Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 21 Jun 2010
Pfizer Prepares for Voluntary Withdrawal of U.S. New Drug Application and for Discontinuation of Commercial Availability of Mylotarg(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
Eisai Provides Preliminary Efficacy Update On EORTC Phase III Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 1 Jul 2008
SuperGen Comments on Preliminary Efficacy Update on EORTC Phase 3 Trial of Dacogen(R) Versus Supportive Care in Patients With Myelodysplastic Syndromes
Biopharmaceuticals Oncology
 HSMN NewsFeed - 20 Sep 2007
European Committee Issues Positive Opinion on Wyeth's TORISEL(TM) for Advanced Renal Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 7 Feb 2007
Bioenvision Files with EMeA for Label Extension of Evoltra(R)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Dec 2006
Pivotal Submission Data Shows Tasigna(R) Achieved Impressive Response Rates In Chronic Myeloid Leukemia Patients No Longer Helped by Gleevec(R)
Biopharmaceuticals Oncology
 HSMN NewsFeed - 12 Sep 2006
Icagen Reports Results of Data Monitoring Committee Meeting in Phase III Assert Trial of ICA-17043
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 5

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 5 additional stories matching:
hydroxyurea
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.